Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021029385 - ONCOLYTIC VACCINIA VIRUS

Publication Number WO/2021/029385
Publication Date 18.02.2021
International Application No. PCT/JP2020/030448
International Filing Date 07.08.2020
IPC
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C12N 7/04 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
04Inactivation or attenuation; Producing viral sub-units
C12N 15/12 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
C12N 15/39 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
34Proteins from DNA viruses
39Poxviridae, e.g. vaccinia virus, variola virus
C12N 15/863 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
863Poxviral vectors, e.g. vaccinia virus
A61K 35/76 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Applicants
  • KMバイオロジクス株式会社 KM BIOLOGICS CO., LTD. [JP]/[JP]
Inventors
  • 村上 利夫 MURAKAMI, Toshio
  • 沖田 剛 OKITA, Go
  • 上水流 結 KAMIZURU, Yui
Agents
  • 山尾 憲人 YAMAO, Norihito
  • 山中 伸一郎 YAMANAKA, Shinichiro
Priority Data
2019-14788509.08.2019JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) ONCOLYTIC VACCINIA VIRUS
(FR) VIRUS DE LA VACCINE ONCOLYTIQUE
(JA) 腫瘍溶解性ワクシニアウイルス
Abstract
(EN)
Provided is an oncolytic virus having both improved safety and productivity. Provided are : a conditionally replicating vaccinia virus which lacks the functions of a vaccinia virus growth factor (VGF), an extracellular signal-regulated kinase (ERK) activation protein, and a ribonucleotide reductase (RNR), is not replicated in a normal cell, is selectively replicable in a proliferative cell, and has improved safety; and a conditionally replicating vaccinia virus which lacks the functions of a VGF, an ERK activation protein, and an RNR, is not replicated in a normal cell, is selectively replicable in a proliferative cell, and has improved safety and productivity, and in which a gene encoding an extracellular enveloped virus (EEV)-related protein is substituted with a gene corresponding to another vaccinia virus strain having a high EEV-producing ability.
(FR)
L'invention concerne un virus oncolytique dont la sécurité et la productivité ont été améliorées. L'invention concerne : un virus de la vaccine à réplication conditionnelle qui est dépourvu des fonctions d'un facteur de croissance du virus de la vaccine (VGF), d'une protéine d'activation kinase régulée par un signal extracellulaire ERK et d'un ribonucléotide réductase (RNR), qui n'est pas répliqué dans une cellule normale, qui est réplicable de manière sélective dans une prolifération cellulaire, et dont la sécurité a été améliorée ; et un virus de la vaccine à réplication conditionnelle qui est dépourvu des fonctions d'un VGF, d'une protéine d'activation ERK, et d'un RNR, qui n'est pas répliqué dans une cellule normale, qui est réplicable de manière sélective dans une prolifération cellulaire, et dont la sécurité et et la productivité ont été améliorées, et dans lequel un gène codant pour un virus enveloppé extracellulaire (EEV) est substitué par un gène correspondant à une autre souche du virus de la vaccine ayant une capacité de production d'EEV élevée.
(JA)
安全性及び生産性ともに向上した腫瘍溶解性ウイルスを提供する。ワクシニアウイルス増殖因子(VGF)、細胞外シグナル調節キナーゼ(ERK)活性化タンパク質、及びリボヌクレオチド還元酵素(RNR)の機能が欠損しており、正常細胞内では複製せず、増殖細胞内で選択的に複製可能な、安全性が向上した制限増殖型ワクシニアウイルス;VGF、ERK活性化タンパク質、及びRNRの機能が欠損しており、さらに、細胞外エンベロープウイルス(EEV)関連タンパク質をコードする遺伝子が、EEV産生能の高い他のワクシニアウイルス株の対応する遺伝子で置換されている、正常細胞内では複製せず、増殖細胞内で選択的に複製可能な、安全性及び生産性が向上した制限増殖型ワクシニアウイルス。
Latest bibliographic data on file with the International Bureau